Chronic migraine often overlaps with metabolic and inflammatory conditions such as obesity, insulin resistance, sleep apnea and depression, which can make treatment more difficult, Acar said
The peptide is not the muscle-builder
A small clinical trial confirmed these findings, showing that exenatide, another GLP-1 agonist, significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension, greatly improving headache symptoms
Retatrutide is still in advanced research stages in many markets
Clinical trials show no significant difference in outcomes between morning and evening injections
When we find out more about how these metabolic pathways mix with each other, it will help us make better plans to treat obesity